Early Aggressive Treatment Strategy against Myasthenia Gravis

2011 ◽  
Vol 65 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Yuriko Nagane ◽  
Shigeaki Suzuki ◽  
Norihiro Suzuki ◽  
Kimiaki Utsugisawa
Keyword(s):  
Myasthenia Gravis ◽  
Treatment Strategy ◽  
Aggressive Treatment

Early fast-acting treatment strategy against generalized myasthenia gravis

2017 ◽  
Vol 381 ◽  
pp. 1082-1083 ◽  
Author(s):  
K. Utsugisawa ◽  
Y. Nagane ◽  
T. Akaishi ◽  
Y. Suzuki ◽  
T. Imai ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Treatment Strategy ◽  
Fast Acting

scholarly journals Baricitinib for Refractory Eosinophilic Fasciitis: Myth or Reality?

2021 ◽  
pp. jrheum.211126
Author(s):  
Gang Wang ◽  
Ning Zhuo ◽  
Jingyang Li
Keyword(s):  
Mycophenolate Mofetil ◽  
Treatment Strategy ◽  
Recent Article ◽  
Considerable Improvement ◽  
Janus Kinase ◽  
Eosinophilic Fasciitis ◽  
Aggressive Treatment

We read the recent article by Sehgal et al with great interest.1 The authors described a 37-year-old patient with eosinophilic fasciitis (EF) who showed no improvement after an initial aggressive treatment strategy (intravenous [IV] methylprednisolone, prednisone, methotrexate, mycophenolate mofetil, and IVIG). Subsequently, the use of the Janus kinase ( JAK) 1/2 inhibitor baricitinib resulted in considerable improvement in the patient's symptoms and skin appearance. However, there are some details that need further clarification.

scholarly journals Early fast‐acting treatment strategy against generalized myasthenia gravis

2017 ◽  
Vol 55 (6) ◽  
pp. 794-801 ◽  
Author(s):  
Kimiaki Utsugisawa ◽  
Yuriko Nagane ◽  
Tetsuya Akaishi ◽  
Yasushi Suzuki ◽  
Tomihiro Imai ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Treatment Strategy ◽  
Fast Acting

scholarly journals Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment

2019 ◽  
Vol 46 (6) ◽  
pp. 762-766
Author(s):  
Alon Abraham ◽  
Leif E. Lovblom ◽  
Vera Bril
Keyword(s):  
Myasthenia Gravis ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Intravenous Immunoglobulins ◽  
Aggressive Treatment ◽  
Mild Disease ◽  
Treatment Regimens ◽  
Low Jitter ◽  
Frequent Exposure

ABSTRACT:To explore whether higher degrees of electrophysiological abnormalities are associated with a more frequent exposure to a more aggressive treatment regimen, we performed a retrospective chart review of patients attending the neuromuscular clinic from June 2012 to December 2015 and included 87 patients. We compared treatment regimens during the follow-up period between patients with high and low jitter and decrement. Myasthenia gravis patients with high jitter or decrement at baseline were more frequently treated with intravenous immunoglobulins (IVIG) and/or plasma exchange (PLEX) during the follow-up period. In patients with mild disease, IVIG or PLEX treatment was associated with high decrement.

Sign in / Sign up

Export Citation Format

Share Document